Disc Medicine (NASDAQ:IRON) had its "buy" rating reaffirmed by analysts at Cowen Inc.
Disc Medicine (NASDAQ:IRON) had its price target raised by analysts at Wells Fargo & Company from $91.00 to $109.00. They now have an "overweight" rating on the stock.
Has Disc Medicine's 2025 Surge Already Gone Too Far After Pipeline Progress Fuels Rally? [Yahoo! Finance]
Disc Medicine (NASDAQ:IRON) had its "strong-buy" rating reaffirmed by analysts at Raymond James Financial, Inc..
Disc Medicine Presents Positive Initial Data from RALLY-MF Phase 2 Trial in Patients with Myelofibrosis (MF) and Anemia at the 67th American Society of Hematology (ASH) Annual Meeting